SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)

1. Name of the drug product:

PAT-OSMIN (Diclofenac Sodium Tablets 50mg)

2. Qualitative and quantitative composition :

Each Uncoated Tablet Contains:

Diclofenac Sodium BP.. . .50mg

Excipients.....q.s.

Approved Colour Used

Sr. No.	Ingredients	Specification	Label Claim / Tablet (In mg)	Over-ages added (In %)	Qty• / Tablet (In mg)	Reason for Function
a)	Dry Mixing (White Part)					
1.	Diclofenac Sodium		50.00		17.55	Medicament
2.	Calcium Hydrogen Phos hate Dih drate				33.06	Diluent
3.	Calcium Carbonate				33.32	Diluent
4.	Maize Starch				66.91	Diluent
5.	Povidone K30				0.59	Binder
b)	Dry Mixing (Yellow Part)					
6.	Diclofenac Sodium		50.00		8.12	Medicament
7.	Calcium Hydrogen Phos hate Dih drate				17.70	Diluent
8.	Calcium Carbonate				17.15	Diluent
9.	Maize Starch			NA	36.25	Diluent
10.	Tartrazine				0.10	Colour

ll.	Povidone K30				0.62	Binder
c)	Dry Mixing (Pink Part)					
12.	Diclofenac Sodium		50.00		8.12	Medicament
13.	Calcium Hydrogen Phos hate Dih drate				17.70	Diluent
14.	Calcium Carbonate				17.15	Diluent
15.	Maize Starch				36.25	Diluent
16.	Erythrosine				0.10	Colour
17.	Povidone K30				0.62	Binder
d)	Dry Mixing (Blue Part)					
18.	Diclofenac Sodium		50.00		16.24	Medicament
19.	Calcium Hydrogen Phos hate Dih drate				35.40	Diluent
20.	Calcium Carbonate				34.30	Diluent
21.	Maize Starch				72.50	Diluent
22.	Brilliant Blue FCF	IHS			0.30	Colour
23.	Povidone K30				1.24	Binder
e)	Binder Preparation (White Part)					
24.	Maize starch				4.25	Binder
25.	Gelatin (Gelling grade)				1.26	Binder
26.	Methyl hydroxybenzoate				0.08	Preservative
27.	Propyl hydroxybenzoate				0.03	Preservative
28.	Purified water					Vehicle
f)	Binder Preparation (Yellow Part)					
29.	Maize starch				3.39	Binder
30.	Gelatin (Gelling grade)				0.78	Binder
31.	Methyl hydroxybenzoate				0.06	Preservative
32.	Propyl hydroxybenzoate				0.03	Preservative
33.	Purified water					Vehicle
g)	Binder Preparation (Pink Part)					

34.	Maize starch				3.39	Binder
35.	Gelatin (Gelling grade)				0.78	Binder
36.	Methyl hydroxybenzoate				0.06	Preservative
37.	Propyl hydroxybenzoate				0.03	Preservative
38.	Purified water					Vehicle
h)	Binder Preparation (Blue Part)					
39.	Maize starch				6.78	Binder
40.	Gelatin (Gelling grade)				1.56	Binder
41.	Methyl hydroxybenzoate				0.12	Preservative
42.	Propyl hydroxybenzoate				0.06	Preservative
43.	Purified water					Vehicle
i)	Lubrication					
44.	Purified Talc				6.00	Glidant
45.	Magnesium Stearate				4.00	Lubricant
46.	Croscarmellose Sodium				6.00	Disintegrant
47.	Colloidal Anhydrous Silica				1.00	Glidant
48.	Maize Starch				9.05	Disintegrant
	Average Weight of Uncoated Tablet (In mg)				520.00	

3 Pharmaceutical form: Uncoated tablet

Description: Multi-coloured, round shaped, biconvex, uncoated tablet, plain on both sides.

4 Clinical Particulars

4.1 Therapeutic indications:

PAT-OSMIN (Diclofenac Sodium Tablets 50 mg) Tablets are indicated for relief of all grades of pain and inflammation in a wide range of conditions, including:

(i) arthritic conditions: rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gout, (ii) acute musculo-skeletal disorders such as periarthritis (for example frozen shoulder), tendinitis, tenosynovitis, bursitis,

(iii) other painful conditions resulting from trauma, including fracture, low back pain, sprains, strains, dislocations, orthopaedic, dental and other minor surgery.

4.2 Posology and method of administration

Route: Oral

Method of Administration:

Posology

Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms.

Adults: 75 mg to 150 mg daily in two or three divided doses.

The recommended maximum daily dose of Diclofenac sodium is 150mg.

4.3 Contraindications

PAT-OSMIN (Diclofenac Sodium Tablets 50 mg) are contraindicated in:

- Hypersensitivity to the active substance or to any of the excipients listed in section 1.3.1.6.1.
- Active, or gastric or intestinal ulcer, bleeding or perforation.
- History of gastrointestinal bleeding or perforation, relating to previous NSAIDs therapy.
- Active, or history Of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding).
- Last trimester of pregnancy (see sections 1.3.1.4.6)
- Hepatic failure
- Renal failure
- Established congestive heart failure (NYHA-II-IV), ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease.
- Like other non-steroidal anti-inflammatory drugs (NSAIDs), diclofenac is also contraindicated in patients in whom attacks of asthma, angiodema, urticaria or acute rhinitis are precipitated by ibuprofen, acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs.

4.4 Special warnings and precautions for use

PAT-OSMIN (Diclofenac Sodium Tablets 50 mg) must not be used in: <u>General</u>

Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms.

The concomitant use of diclofenac with systemic NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided due to the absence of any evidence demonstrating synergistic benefits and the potential for additive undesirable effects

Caution is indicated in the elderly on basic medical grounds. In particular, it is recommended that the lowest effective dose be used in frail elderly patients or those with a low body weight

As with other nonsteroidal anti-inflammatory drugs including diclofenac, allergic reactions, including anaphylactic/Anaphylactoid reactions, can also occur without earlier exposure to the drug Hypersensitivity reactions can also progress to Kounis syndrome, a serious allergic reaction that can result in myocardial infarction. Presenting symptoms of such reactions can include chest pain occurring in association with an allergic reaction to diclofenac.

Like other NSAIDs, diclofenac may mask the signs and symptoms of infection due to its

pharmacodynamic properties.
This medicine contains lactose and therefore is not recommended for patients with rare hereditary problems of galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption.

Gastrointestinal effects

Gastrointestinal bleeding (haematemesis, melaena), ulceration or perforation, which can be fatal has been reported with all NSAIDs including diclofenac, and may occur at any time during treatment, with or without warning symptoms or a previous history of serious gastrointestinal (GI) events. They generally have more serious consequences in the elderly. If gastrointestinal bleeding or ulceration occurs in patients receiving diclofenac, the medicinal product should be withdrawn. As with all NSAIDs, including diclofenac, close medical surveillance is imperative and panicular caution should be exercised when prescribing diclofenac in patients with symptoms indicative of gastrointestinal disorders or with a history suggestive of gastric or intestinal ulceration, bleeding or perforation. The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses including diclofenac and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation.
The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal.
To reduce the risk of GI toxicity in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation, and in the elderly, the treatment should be initiated and maintained at the lowest effective dose.
Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant use of medicinal products containing low dose acetylsalicylic acid (ASA/aspirin), or other medicinal products likely to increase gastrointestinal risk.
Patients with a history of GI toxicity, particularly the elderly, should report any unusual abdominal symptoms (especially GI bleeding).
Caution is recommended in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as systemic corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors (SSRIs) or anti-platelet agents such as acetylsalicylic acid.
Close medical surveillance and caution should also be exercised in patients with ulcerative colitis or Crohn's disease, as their condition may be exacerbated (see sections 1.3.1.4.8).
NSAIDs, including diclofenac, may be associated with increased risk of gastro-intestinal anastomotic leak. Close medical surveillance and caution are recommended when using diclofenac after gastro-intestinal surgery.

Hepatic impairment

Close medical surveillance is required when prescribing diclofenac to patients with impairment of hepatic function, as their condition may be exacerbated.
As with other NSAIDs, including diclofenac, values of one or more liver enzymes may increase. During prolonged treatment with diclofenac, regular monitoring of hepatic function is indicated as a precautionary measure.
If abnormal liver function tests persist or worsen, clinical signs or symptoms consistent with liver disease develop, or if other manifestations occur (eosinophilia, rash), diclofenac should be discontinued.
Hepatitis may occur with diclofenac without prodromal symptoms.
Caution is called for when using diclofenac in patients with hepatic porphyria, since it may trigger an attack.

S

Renal impairment

As fluid retention and oedema have been reported in association with NSAID therapy, including diclofenac, particular caution is called for in patients with impaired cardiac or renal function, history of hypertension, the elderly, patients receiving concomitant treatment with diuretics or medicinal products that can significantly impact renal function, and in those patients with substantial extracellular volume depletion from any cause, e.g. before or after major surgery. Monitoring of renal function is recommended as a precautionary measure when using diclofenac in such cases. Discontinuation of therapy is usually followed by recovery to the pre-treatment state.

Skin effects

Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs, including Diclofenac. Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. Diclofenac sodium tablets should be discontinued at the first appearance of skin rash, mucosal lesions or any other signs of hypersensitivity.

SLE and mixed connective tissue disease

In patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders there may be an increased risk of aseptic meningitis.

Cardiovascular and cerebrovascular effects

Patients with congestive heart failure (NYHA-I) or patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with diclofenac after careful consideration. As the cardiovascular risks of diclofenac may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically.

Appropriate monitoring and advice are required for patients with a history of hypertension and congestive heart failure (NYHA-I) as fluid retention and oedema have been reported in association with NSAID therapy including diclofenac.

Clinical trial and epidemiological data consistently point towards increased risk of arterial thrombotic events (for example myocardial infarction or stroke) associated with the use of diclofenac, particularly at high dose (150mg daily) and in long term treatment.

Patients should remain alert for the signs and symptoms of serious arteriothrombotic events (e.g. chest pain, shortness of breath, weakness, slurring of speech), which can occur without warnings. Patients should be instructed to see a physician immediately in case of such an event.

Haematological effects

During prolonged treatment With diclofenac, as with other NSAIDs, monitoring of the blood count is recommended.

Diclofenac may reversibly inhibit platelet aggregation (see anticoagulants in sections 1.3.1.4.5). Patients with defects of haemostasis, bleeding diathesis or haematological abnormalities should be carefully monitored.

Pre-existing asthma

In patients with asthma, seasonal allergic rhinitis, swelling of the nasal mucosa (i.e. nasal polyps), chronic obstructive pulmonary diseases or chronic infections of the respiratory tract (especially if linked to allergic rhinitis-like symptoms), reactions on NSAIDs like asthma exacerbations (socalled intolerance to analgesics / analgesics-asthma), Quincke's oedema or urticaria are more frequent than in other patients. Therefore, special precaution is recommended in such patients (readiness for emergency). This is applicable as well for patients who are allergic to other substances, e.g. with skin reactions, pruritus or urticaria.
Like other drugs that inhibit prostaglandin synthetase activity, diclofenac sodium and other NSAIDs can precipitate bronchospasm if administered to patients suffering from, or with a previous history of bronchial asthma.

4.5 Interaction with other medicinal products and other forms of interaction Aspirin
The following interactions include those observed with diclofenac tablets and/or other pharmaceutical forms of diclofenac.
Lithium: If used concomitantly, diclofenac may raise plasma concentrations of lithium. Monitoring of the serum lithium level is recommended.

Digoxin: If used concomitantly, diclofenac may raise plasma concentrations of digoxin. Monitoring of the serum digoxin level is recommended.

Diuretics and Anti-hypertensive agents: Like other NSAIDs, concomitant use of diclofenac with diuretics or antihypertensive agents (e.g. beta-blockers, angiotensin converting enzyme (ACE) inhibitors) may cause a decrease in their antihypertensive effect via inhibition of vasodilatory prostaglandin synthesis.
Therefore, the combination should be administered With caution and patients, especially the elderly, should have their blood pressure periodically monitored. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter, particularly for diuretics and ACE inhibitors due to the increased risk of nephrotoxicity.

Drugs known to cause hyperkalemia: Concomitant treatment with potassium-sparing diuretics, ciclosporin, tacrolimus or trimethoprim may be associated with increased serum potassium levels, which should therefore be monitored frequently (see sections 1.3. I .4.4).

Anticoagulants and anti-platelet agents: Caution is recommended since concomitant administration could increase the risk of bleeding (see sections 1.3.1.4.4). Although clinical investigations do not appear to indicate that diclofenac affects the action of anticoagulants, there are reports of an increased risk of haemorrhage in patients receiving diclofenac and anticoagulants concomitantly (see sections 1.3.1.4.4). Therefore, to be certain that no change in anticoagulant dosage is required, close monitoring of such patients is required. As with other nonsteroidal antiinflammatory agents, diclofenac in high dose can reversibly inhibit platelet aggregation.

Other NSAIDS including cyclo-oxygenase-2selective inhibitors and corticosteroids: Coadministration of diclofenac and other systemic NSAIDs or corticosteroids may increase the risk of gastrointestinal bleeding or ulceration. Avoid concomitant use of two or more NSAIDs (see sections 1.3.1.4.4).
Selective serotonin reuptake inhibitors (SSRIs): Concomitant administration of SSRIs may increase the risk of gastrointestinal bleeding (see sections 1.3.1.4.4).

Antidiabetics: Clinical studies have shown that diclofenac can be given together with oral antidiabetic agents without influencing their clinical effect. However, there have been isolated reports of hypoglycaemic and hyperglycaemic effects necessitating changes in the dosage of the antidiabetic agents during treatment with diclofenac. For this reason, monitoring of the blood glucose level is recommended as a precautionary measure during concomitant therapy.

Methotrexate: Diclofenac can inhibit the tubular renal clearance of methotrexate hereby increasing methotrexate levels. Caution is recommended when NSAIDs, including diclofenac, are administered less than 24 hours before treatment with methotrexate, since blood concentrations of methotrexate may rise and the toxicity of this substance be increased.

Cases of serious toxicity have been reported when methotrexate and NSAIDs including diclofenac are given within 24 hours of each other. This interaction is mediated through accumulation of methotrexate resulting from impairment of renal excretion in the presence of the NSAID.

Ciclosporin: Diclofenac, like Other NSAIDs, may increase the nephrotoxicity of ciclosporin due to the effect on renal prostaglandins. Therefore, it should be given at doses lower than those that would be used in patients not receiving ciclosporin.

Tacrolimus: Possible increased risk of nephrotoxicity when NSAIDs are given with tacrolimus. This might be mediated through renal antiprostagladin effects of both NSAID and calcineurin inhibitor.

Quinolone antimicrobials: Convulsions may occur due to an interaction between quinolones and NSAIDs. This may occur in patients with or without a previous history of epilepsy or convulsions. Therefore, caution should be exercised when considering the use of a quinolone in patients who are already receiving an NSAID.

Phenytoin: When using phenytoin concomitantly with diclofenac, monitoring of phenytoin plasma concentrations is recommended due to an expected increase in exposure to phenytoin.

Colestipol and cholestyramine: These agents can induce a delay or decrease in absorption of diclofenac. Therefore, it is recommended to administer diclofenac at least one hour before or 4 to 6 hours after administration of colestipol/ cholestyramine.

Cardiac glycosides: Concomitant use of cardiac glycosides and NSAIDs in patients may exacerbate cardiac failure, reduce GFR and increase plasma glycoside levels.

Mifepristone: NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs can reduce the effect of mifepristone.

Potent CYP2C9 inhibitors: "Caution is recommended when co-prescribing diclofenac with potent CYP2C9 inhibitors (such as sulfinpyrazone and voriconazole), which could result in a significant increase in peak plasma concentration and exposure to diclofenac due to inhibition of diclofenac metabolism.

4.6 Pregnancies and Lactation:

Pregnancy

Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5 %.

The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality.
In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.
During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:

- cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension);
- renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and the neonate, at the end of pregnancy, to:
- possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses.
- inhibition of uterine contractions resulting in delayed or prolonged labour.

Consequently, diclofenac sodium tablets are contraindicated during the third trimester of pregnancy.

Breast-feeding:
Like other NSAIDs, diclofenac passes into the breast milk in small amounts. Therefore, diclofenac should not be administered during breast feeding in order to avoid undesirable effects in the infant (see section 1.3.1.5.2).

Femaile Fertility

As with other NSAIDs, the use of diclofenac may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of diclofenac should be considered (see also section 1.3.1.4.4 regarding female fertility).

4.7 Effects on the ability to drive and use machines

Patients who experience visual disturbances, dizziness, vertigo, somnolence central nervous system disturbances, drowsiness or fatigue while taking NSAIDs should refrain from driving or operate machinery.

4.8 Undesirable effects

- Cardiovascular Thrombotic Events •GI Bleeding, Ulceration and Perforation
- Hepatotoxicity
- Hypertension
- Heart Failure and Edema
- Renal Toxicity and Hyperkalemia
- Anaphylactic Reactions
- Serious Skin Reactions
- Hematologic Toxicity

4.9 Overdoses

Symptoms
There is no typical clinical picture resulting from diclofenac over dosage. Over dosage can cause symptoms such as headache, nausea, vomiting, epigastric pain, gastrointestinal haemorrhage, diarrhoea, dizziness, disorientation, excitation, coma, drowsiness, tinnitus, fainting or convulsions.

In the case of significant poisoning acute renal failure and liver damage are possible. Therapeutic measures

Management of acute poisoning with NSAIDs, including diclofenac, essentially consists of supportive measures and symptomatic treatment. Supportive measures and symptomatic treatment should be given for complications such as hypotension, renal failure, convulsions, gastrointestinal disorder, and respiratory depression.

Special measures such as forced diuresis, dialysis or haemo-perfusion are probably of no help in eliminating NSAIDs, including diclofenac, due to the high protein binding and extensive metabolism.

Activated charcoal may be considered after ingestion of a potentially toxic overdose, and gastric decontamination (e.g. vomiting, gastric lavage) after ingestion of a potentially life threatening overdose

5 Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Non-steroidal anti-inflammatory drugs (NSAlDs).

Mechanism of action:

Diclofenac sodium is a non-steroidal agent with marked analgesic/anti inflammatory properties. It is an inhibitor of prostaglandin synthetase, (cyclo-oxygenase).

Diclofenac sodium in vitro does not suppress proteoglycan biosynthesis in cartilage at concentrations equivalent to the concentrations reached in human beings.

5.2 Pharmacokinetic properties

Absorption

Absorption is complete but onset is delayed until passage through the stomach, which may be affected by food which delays stomach emptying. The mean peak plasma diclofenac concentration reached at about 2 hours (50mg dose produces 1511± 466 ng/ml).

Distribution

The active substance is 99.7% protein bound, mainly to albumin (99.4%).

Diclofenac enters the synovial fluid, where maximum concentrations are measured 2-4 hours after the peak plasma values have been attained. The apparent half-life for elimination from the synovial fluid is 3-6 hours. Two hours after reaching the peak plasma values, concentrations of the active substance are already higher in the synovial fluid than they are in the plasma and remain higher for up to 12 hours.

Diclofenac was detected in a low concentration (100 ng/mL) in breast milk in one nursing mother. The estimated amount ingested by an infant consuming breast milk is equivalent to a 0.03 mg/kg/day dose (see sections 1.3.1.4.6).

Metabolism

Biotransformation of diclofenac takes place partly by glucuronidation of the intact molecule, but mainly by single and multiple hydroxylation and methoxylation, resulting in several phenolic metabolites, most of which are converted to glucuronide conjugates. Two phenolic metabolites are biologically active, but to a much lesser extent than diclofenac. Elimination

The total systemic clearance of diclofenac in plasma is 263 ± 56 mL/min (mean value ± SD). The terminal half-life in plasma is 1-2 hours. Four of the metabolites, including the two active ones, also have short plasma half-lives of 1-3 hours.

About 60% of the administered dose is excreted in the urine in the form of the glucuronide conjugate of the intact molecule and as metabolites, most of which are also converted to glucuronide

conjugates. Less than 1% is excreted as unchanged substance. The rest of the dose is eliminated as metabolites through the bile in the faeces.

5.3 Preclinical safety Data

None stated

6 Pharmaceutical particulars

6.1 List of excipients

- Calcium Hydrogen Phosphate Dihydrate
- Calcium carbonate
- Maize Starch
- Povidone K30
- Tartrazine
- Erythrosine
- Brilliant Blue FCF
- Gelatin (Gelling grade)
- Methyl hydroxybenzoate
- Propyl hydroxybenzoate
- Purified talc
- Magnesium stearate
- Colloidal anhydrous silica
- Croscarmellose sodium

6.2 Incompatibilities Not applicable

6.3 Shelf life 36 months

6.4 Special precautions for storage

Store below 30^0 C in a dry & dark place. Keep all medicines out of reach of children.

6.5 Nature and contents of container

Primary packing: 12 Tablets in an ALU-PVC blister.

Secondary packing: 1 Blister is packed in an inner carton along with leaflet.

Tertiary packing: 20 Inner canons are packed in an outer carton. Shrink individual outer carton. Such 48 Shrinks are packed in a 5 Ply corrugated box sealed with BOPP tape & strap with strapping roll.

7 Applicant / Manufacturer Applicant

Applicant name and address	M/s. PATBLESS PHARMACEUTICAL LIMITED No. 12, Fabkez Drive, Omagba Phase Onitsha, Anambra State, Ni eria
Contact person's phone number	

Contact person's email	

Manufacturer

Manufacturer name and address	M/s. IMPULSE PHARMA PVT. LTD. J-201, J002/1 , MIDC Tarapur, Boisar, Dist. Palghar - 401506, Maharashtra State, India.
Contact erson's hone number	+91 7350864803
Contact person's email	pravin.patil@kamlagroup.co.in

1 x 12 TABLETS

PAT-OSMIN

Diclofenac Sodium Tablets 50 mg

IMPULSE PHARMA PVT. LTD.

PAT-OSMIN
Diclofenac Sodium Tablets 50 mg

PAT-OSMIN
Diclofenac Sodium Tablets 50 mg

Composition:
Each uncoated tablet contains :
Diclofenac Sodium BP 50 mg
Excipients q.s.
Approved colour used.

Dosage: As directed by the Physician.

Storage: Store below 30°C in a dry & dark place.

Keep all medicines out of reach of children.

Read leaflet carefully before use.

Manufactured by:
IMPULSE
J-201, J-202/1, MIDC Tarapur,
Boisar, Dist. Palghar-401 506,
Maharashtra State, India.
Email : info@kantilagroup.co.in
Website : www.kantilagroup.co.in

NAFDAC Reg. No.: B4-9185

Mfg. Lic. No.: KD/641

Batch No.:

Mfg. Date:

Exp. Date:

UV WINDOW

BARCODE

Marketed by:
Petbless Pharmaceutical Limited
No. 12, Fabkez Drive, Omagba Phase
Onitsha, Anambra State, Nigeria
Anambra State.

PAT-OSMIN
Diclofenac Sodium Tablets 50 mg

IMPULSE PHARMA PVT. LTD.

PAT-OSMIN

Diclofenac Sodium Tablets 50 mg

1 x 12 TABLETS

1 x 12 TABLETS

PAT-OSMIN

Diclofenac Sodium Tablets 50 mg

IMPULSE